Loading...
Market
Type of first product from Moderna-OpenAI collaboration
4
Resolution / Starting Odds
Vaccine • 34%
Cancer treatment • 33%
Other therapeutic • 33%
Product announcements from Moderna or OpenAI, press releases, or verified media reports
Story
Moderna, OpenAI to Develop 15 New Products, Transform Biotech with AI
Apr 29, 2024, 08:16 AM
Moderna has entered into a significant collaboration with OpenAI to integrate artificial intelligence across its operations. This partnership, as reported by multiple sources including the Wall Street Journal, aims to transform Moderna's approach to biotechnology by automating nearly every business process and enhancing the productivity of its workforce. Sam Altman, OpenAI's CEO, stated that AI will increasingly perform more science, aiming to enhance productivity and accelerate capabilities. The collaboration, which began in early 2023, includes the deployment of Moderna's own version of ChatGPT, named mChat, achieving over 80% internal adoption. Moderna has also created over 400 GPTs for research tasks. The companies plan to develop 15 new products over the next five years, focusing on life-saving vaccines and individualized cancer treatments. OpenAI provides dedicated support to Moderna, including weekly strategy calls and a shared communication channel for quick problem-solving.
View original story
Similar markets
Oncology • 25%
Cardiovascular • 25%
Neurology • 25%
Immunology • 25%
In Vivo Therapy • 33%
Ex Vivo Therapy • 33%
Diagnostic Tool • 34%
Spikevax • 33%
RSV vaccine • 33%
Other • 34%
Ad-targeting tool • 33%
Content recommendation engine • 33%
Automated content creation tool • 34%
Moderna forms new partnerships • 25%
Pfizer/BioNTech forms new partnerships • 25%
Both companies form new partnerships • 25%
No new partnerships formed • 25%
AI-generated news summaries • 33%
AI-assisted investigative journalism • 33%
AI-powered reader engagement tools • 33%
Positive impact • 33%
Negative impact • 33%
No significant impact • 34%
Under $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
USA • 25%
Canada • 25%
UK • 25%
Australia • 25%
Moderna • 33%
Pfizer • 33%
University of Pennsylvania • 33%
Phase 3 trial initiation • 33%
Phase 3 trial completion • 33%
FDA submission • 34%